Mexico Alcohol Addiction Therapeutics Market Analysis

Mexico Alcohol Addiction Therapeutics Market Executive Summary

The Mexico Alcohol Addiction Therapeutics Market is valued at around $11 Mn in 2022 and is projected to reach $18 Mn by 2030, exhibiting a CAGR of 6.55% during the forecast period.

Alcohol addiction, sometimes referred to as alcoholism or alcohol use disorder (AUD), is a chronic illness marked by an inability to regulate or abstain from alcohol consumption despite its detrimental effects. It is seen as a progressive illness with major potential effects on one's social, mental, and physical well-being. A mix of hereditary, environmental, and psychological variables impact alcohol addiction. It may have detrimental effects on one's physical well-being. Combining counselling, support groups, and behavioural therapy is a common approach to treating alcoholism. Medication may occasionally be recommended to treat withdrawal symptoms or lessen cravings.

In Mexico, the typical age of onset for alcohol usage is between 16 and 17 years. Binge drinking (5+ drinks on each occasion) has grown dramatically in recent years. Alcohol dependency was reported by more than 2.2% of the population aged 12 to 65. Men have a larger incidence than women (3.9% vs. 0.6%). The market is fuelled by drivers such as increasing prevalence, an increase in the efforts taken by the government to battle addiction, and the adoption of newer advanced technologies by the general population.

International firms with well-known names like naltrexone and acamprosate, such as AbbVie and Otsuka, control a large portion of the market. They may have an advantage in generating income due to their extensive worldwide reach and marketing resources. While local companies may not have as large a market share as global companies, they can still gain from cost-competitive production and can concentrate on meeting particular local demands. Businesses in narrow markets like Farmacéutica Serral and Genomma generate substantial income.

Market Dynamics

Market Drivers

Increasing Prevalence: Alcohol consumption is a serious and expanding issue in Mexico. There is a great need for efficient treatment alternatives due to the high incidence of dependency and binge drinking. Rising spending rates, especially among youth, are a result of increased urbanization and exposure to Western lifestyles.

Government Initiatives: The Mexican government is investing more in programs for addiction treatment and extending healthcare coverage. This increases the accessibility of therapies for a greater number of people. Recognizing the business opportunity, private healthcare providers are also making investments to provide addiction treatment services.

Advancements in Technology: More efficient and individualized treatment alternatives are made possible by the creation of novel pharmaceuticals and non-pharmacological therapies like behavioural therapy and digital interventions. The community has become more and more acquainted with telemedicine and remote monitoring platforms as a result of technological improvements. By facilitating greater access to care for those with restricted mobility or in distant places, this can enhance the expansion of the industry.

Market Restraints

Lack of Resources: Underdeveloped infrastructure is typical in Mexico. In Mexico, there is a dearth of licensed addiction counsellors and specialists. Nearly everywhere in the county, there is a constant need for experts and superspecialists, especially in underprivileged communities. This may reduce the variety of therapeutic alternatives accessible and result in lengthy wait times for access to treatment.

Cost of Treatment: A significant fraction of the Mexican population cannot afford the high cost of several helpful drugs, such as acamprosate and naltrexone. Insurance for addiction treatment varies and frequently does not cover all necessary drugs or just covers a portion of it. Evidence-based therapies may face competition from traditional and informal therapy modalities, such as faith-based programs or herbal cures, which may have an adverse influence on their efficacy and reach.

Social Barriers: The stigma associated with addiction on the part of society might discourage people from getting treatment or seeking assistance. A lack of knowledge about available services and treatment alternatives may make this worse.

Healthcare Policies and Regulatory Landscape

The national health policy and the regulation of pharmaceuticals and medical devices in Mexico are within the purview of the Mexican Secretariat of Health. The decentralized and independent Federal Committee for Protection from Sanitary Risks (COFEPRIS) is in charge of policing health facilities, enforcing sanitary regulations over advertising, and keeping an eye on the production, import, and export of medical supplies. Mexico's pharmaceutical industry is governed by COFEPRIS, which also maintains a strong healthcare system and well-established regulatory framework that make it an attractive place for businesses to operate. In Mexico, COFEPRIS is also in charge of overseeing clinical research regulations. The organization is modernizing to digitize its processes and increase transparency, in line with the government's goals of thwarting corruption and enhancing the management of public resources.

Competitive Landscape

Key Players

• Elli Lily
• Roche
• AbbVie
• TEVA
• Otsuka Pharmaceuticals
• GlaxoSmithKline
• Johnson & Jhonson
• Viatris
• Grupo Ferrer
• Genomma